Patents by Inventor Kal Lindenstruth

Kal Lindenstruth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
    Publication number: 20220241260
    Abstract: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.
    Type: Application
    Filed: October 29, 2020
    Publication date: August 4, 2022
    Inventors: Ashish Chatterji, Jingjun Huang, Stephanie Koennings, Kal Lindenstruth, Harpreet Sandhu, Navnit Shah
  • Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
    Publication number: 20210052567
    Abstract: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.
    Type: Application
    Filed: October 29, 2020
    Publication date: February 25, 2021
    Inventors: Ashish Chatterji, Jingjum Huang, Stephanie Koennings, Kal Lindenstruth, Harpreet Sandhu, Navnit Shah
  • Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
    Publication number: 20190216789
    Abstract: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (FRD) and Fragile X Syndrome.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Inventors: Ashish Chatterji, Jingjum Huang, Stephanie Koennings, Kal Lindenstruth, Harpreet Sandhu, Navnit Shah